Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2020 1
2021 4
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Spatial Extent of Amyloid-beta Levels and Associations With Tau-PET and Cognition.
Ozlen H, Pichet Binette A, Köbe T, Meyer PF, Gonneaud J, St-Onge F, Provost K, Soucy JP, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative, the Harvard Aging Brain Study, the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease Research Group. Ozlen H, et al. Among authors: provost k. JAMA Neurol. 2022 Oct 1;79(10):1025-1035. doi: 10.1001/jamaneurol.2022.2442. JAMA Neurol. 2022. PMID: 35994280 Free PMC article.
IMPORTANCE: Preventive trials of anti-amyloid agents might preferably recruit persons showing earliest biologically relevant beta-amyloid (Abeta) binding on positron emission tomography (PET). OBJECTIVE: To investigate the timing at which Abeta-PET binding starts sh …
IMPORTANCE: Preventive trials of anti-amyloid agents might preferably recruit persons showing earliest biologically relevant beta-amyloid (A …
Abnormal tau in amyloid PET negative individuals.
Yoon B, Guo T, Provost K, Korman D, Ward TJ, Landau SM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative. Yoon B, et al. Among authors: provost k. Neurobiol Aging. 2022 Jan;109:125-134. doi: 10.1016/j.neurobiolaging.2021.09.019. Epub 2021 Sep 30. Neurobiol Aging. 2022. PMID: 34715443 Free PMC article.
We examined the characteristics of individuals with biomarker evidence of tauopathy but without beta-amyloid (Abeta) (A-T+) in relation to individuals with (A+T+) and without (A-T-) evidence of Alzheimer's disease (AD). We included 561 participants with Abeta and tau PET f …
We examined the characteristics of individuals with biomarker evidence of tauopathy but without beta-amyloid (Abeta) (A-T+) in relation to i …
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, Provost K, Soucy JP, Buckley RF, Benzinger TLS, Morris JC, Villemagne VL, Doré V, Sperling RA, Johnson KA, Rowe CC, Gordon BA, Poirier J, Breitner JCS, Villeneuve S; PREVENT-AD, HABS, and AIBL Research Groups. Strikwerda-Brown C, et al. Among authors: provost k. JAMA Neurol. 2022 Oct 1;79(10):975-985. doi: 10.1001/jamaneurol.2022.2379. JAMA Neurol. 2022. PMID: 35907254 Free PMC article.
Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid beta and tau positron emission tomography (PET). Median clinical follow-up after PET ranged from 1.94 to 3.66 years. EXPOSURES: Based on binary asse …
Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid beta and tau positron …
Symptomatic amyloid-related imaging abnormalities in an APOE epsilon4/epsilon4 patient treated with aducanumab.
VandeVrede L, Gibbs DM, Koestler M, La Joie R, Ljubenkov PA, Provost K, Soleimani-Meigooni D, Strom A, Tsoy E, Rabinovici GD, Boxer AL. VandeVrede L, et al. Among authors: provost k. Alzheimers Dement (Amst). 2020 Oct 9;12(1):e12101. doi: 10.1002/dad2.12101. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 33072846 Free PMC article.
Subsequent clinical/imaging worsening prompted a course of methylprednisolone. Symptoms and ARIA-E resolved over 6 months, while ARIA-H persisted. Quantitative analysis of interval amyloid PET showed reduced signal in pre-existing areas but increased signal posterio …
Subsequent clinical/imaging worsening prompted a course of methylprednisolone. Symptoms and ARIA-E resolved over 6 months, while ARIA …
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.
Provost K, Iaccarino L, Soleimani-Meigooni DN, Baker S, Edwards L, Eichenlaub U, Hansson O, Jagust W, Janabi M, La Joie R, Lesman-Segev O, Mellinger TJ, Miller BL, Ossenkoppele R, Pham J, Smith R, Sonni I, Strom A, Mattsson-Carlgren N, Rabinovici GD; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Provost K, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2259-2271. doi: 10.1007/s00259-020-05152-8. Epub 2021 Jan 4. Eur J Nucl Med Mol Imaging. 2021. PMID: 33398408 Free PMC article.
PURPOSE: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer's Disease (AD) Research Framework derived from [(18)F]flortaucipir (FTP) PET visual assessment, FTP quantification, and cerebrospinal fluid (CSF) phosphorylated Tau-181 (PTau181). ...CO …
PURPOSE: To compare rates of tau biomarker positivity (T-status) per the 2018 Alzheimer's Disease (AD) Research Framework derived from [(18) …
Evaluation of [(18)F]-JNJ-64326067-AAA tau PET tracer in humans.
Baker SL, Provost K, Thomas W, Whitman AJ, Janabi M, Schmidt ME, Timmers M, Kolb HC, Rabinovici GD, Jagust WJ. Baker SL, et al. Among authors: provost k. J Cereb Blood Flow Metab. 2021 Dec;41(12):3302-3313. doi: 10.1177/0271678X211031035. Epub 2021 Jul 14. J Cereb Blood Flow Metab. 2021. PMID: 34259071 Free PMC article. Clinical Trial.
Seventeen subjects (4 HCs, 5 MCIs, 5 ADs, and 3 PSPs) received a [(11)C]-PIB amyloid PET scan, and a tau [(18)F]-JNJ-067 PET scan 0-90 minutes post-injection. ...
Seventeen subjects (4 HCs, 5 MCIs, 5 ADs, and 3 PSPs) received a [(11)C]-PIB amyloid PET scan, and a tau [(18)F]-JNJ-067 PET s …
Crossed cerebellar diaschisis on (18)F-FDG PET: Frequency across neurodegenerative syndromes and association with (11)C-PIB and (18)F-Flortaucipir.
Provost K, La Joie R, Strom A, Iaccarino L, Edwards L, Mellinger TJ, Pham J, Baker SL, Miller BL, Jagust WJ, Rabinovici GD. Provost K, et al. J Cereb Blood Flow Metab. 2021 Sep;41(9):2329-2343. doi: 10.1177/0271678X211001216. Epub 2021 Mar 10. J Cereb Blood Flow Metab. 2021. PMID: 33691512 Free PMC article.
We used (18)F-FDG-PET to investigate the frequency of crossed cerebellar diaschisis (CCD) in 197 patients with various syndromes associated with neurodegenerative diseases. In a subset of 117 patients, we studied relationships between CCD and cortical asymmetry of Alzheime …
We used (18)F-FDG-PET to investigate the frequency of crossed cerebellar diaschisis (CCD) in 197 patients with various syndromes asso …
Reproducibility of Lobar Perfusion and Ventilation Quantification Using SPECT/CT Segmentation Software in Lung Cancer Patients.
Provost K, Leblond A, Gauthier-Lemire A, Filion É, Bahig H, Lord M. Provost K, et al. J Nucl Med Technol. 2017 Sep;45(3):185-192. doi: 10.2967/jnmt.117.191056. Epub 2017 Apr 13. J Nucl Med Technol. 2017. PMID: 28408698 Free article.
However, subdividing lung parenchyma into rectangular regions of interest, as done on planar images, is a poor reflection of true lobar anatomy. New tridimensional methods using SPECT and SPECT/CT have been introduced, including semiautomatic lung segmentation software. .. …
However, subdividing lung parenchyma into rectangular regions of interest, as done on planar images, is a poor reflection of true lob …